PT - JOURNAL ARTICLE AU - Buckley, Rita ED - Kastrati, Adnan TI - ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding DP - 2011 01 TA - MD Conference Express PG - 14--15 VI - 11 IP - 15 4099 - http://mdc.sagepub.com/content/11/15/14.short 4100 - http://mdc.sagepub.com/content/11/15/14.full AB - A strategy of intravenous abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) plus unfractionated heparin, compared with bivalirudin, an IV direct thrombin inhibitor, failed to improve clinical outcomes and increased the risk of bleeding in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention, according to results of the ISAR-REACT 4 trial [NCT00373451].